Regulators hit Italian drugmaker with warning over manufacturing issues

Pills in blisters
Regulators hit ICI International Chemical Industry for failing to comply with good manufacturing practices at its Cellole, Italy plant. (Shutterstock)

Italian regulators slapped a warning letter on ICI International Chemical Industry for failing to comply with good manufacturing practices at its Cellole, Italy plant.

The Italian Medicines Agency found in a March 22 inspection of the facility that there were 19 major and nine other deficiencies related to “inadequate pharmaceutical quality systems that resulted in a number of issues.”

Those issues included poor deviations management and investigation, lack of documentation handling, lack of cleaning validation, lack of process validation, as well as a lack of analytical review and method validation and poor computer system validation.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The agency called for the suspension of the company’s manufacturing authorization and withdrawal of its current valid GMP certificate.

The IMA cited the drug Spherotide (triptorelin), which is used to treat prostate cancer, in its letter posted on the EudraGDMP website.

According to a Bloomberg company profile, International Chemical was founded in 1989 and manufactures, fabricates or processes pharmaceuticals for human and veterinary use.

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.